According to the results of a phase 2 clinical trial published in The Lancet Haematology , the DAV regimen, composed of intravenous daunorubicin, intravenous cytarabine, and oral venetoclax, represents an effective induction therapy for newly diagnosed adults with acute myeloid leukaemia (AML), with high rates of complete remission.

The analysis...